Table 2.
Major kidney disease etiologies, and detailed information on baseline characteristics, treatments, and outcomes
| Kidney disease | N | eGFR | UPCR | Chronicity Score | IS treatment | IBD treatment modification after kidney disease diagnosis | Kidney failure | Remission or changes in KF |
|---|---|---|---|---|---|---|---|---|
| IgAN | 24 (22) | 37 (24–81) | 0.7 (0.4–1.4) | 3 (2–3) | None: 16 (67) CS: 6 (25) CS + MMF: 2 (8) |
None: 18 (75) Ustekinumab: 3 (13) Infliximab: 2 (8) Adalimumab: 2 (8) |
5 (21) | No remission: 14 (58) Partial: 3 (13) Complete: 7 (29) |
| IgA vasculitis | 5 (5) | 47 (34-104) | 1.3 (0.9-2.3) | 1 (1–2) | None: 1 (20) CS: 2 (40) CS + MMF: 2 (40) |
None: 4 (80) Vedolizumab: 1 (20) |
0 (0) | No remission: 2 (40) Partial: 1 (20) Complete: 2 (40) |
| CIN | 21 (19) | 26 (15–33) | 0.7 (0.2–0.7) | 3 (3–4) | None: 9 (43) CS: 11 (52) CS+MMF: 1 (5) |
None: 16 (75) Azathioprine: 2 (10) Adalimumab: 1 (5) Vedolizumab: 1 (5) Budesonide: 1 (5) |
8 (38) | Decline of KF: 15 (71) Stabilization of KF: 4 (19) Improvement of KF: 2 (10) |
| AIN | 14 (13) | 21 (13–32) | 0.4 (0.1–1.5) | 2 (1–2) | None: 5 (36) CS: 6 (43) CS+MMF: 3 (21) |
None: 6 (44) Ustekinumab: 3 (21) Vedolizumab: 1 (7) Budesonide: 1 (7) Azathioprine: 1 (7) Infliximab: 2 (14) |
2 (14) | Decline of KF: 7 (50) Stabilization of KF: 3 (21) Improvement of KF: 4 (29) |
| ATN | 4 (4) | 10 (7–13) | 0.7 (0.2–1.9) | 2 (1–2) | None: 3 (75) CS: 1 (25) |
Adalimumab: 3 (75) Azathioprine: 1 (25) |
0 (0) | Stabilization of KF: 2 (50) Improvement of KF: 2 (50) |
| Arteriosclerosis without specific changes and severe glomerulosclerosis | 9 (8) | 22 (17–42) | 0.3 (0.2–1.6) | 3 (3–4) | None: 9 (100) | None: 7 (78) Adalimumab: 2 (22) |
5 (56) | Decline of: 8 (89) Stabilization of KF: 1 (11) |
| Secondary FSGS | 4 | 54 (27–86) | 1 (0.6–2.9) | 3 (2–3) | None: 4 (100) | Vedolizumab: 1 (25) | 1 (25) | No remission: 4 (100) |
| Diabetic nephropathy | 3 | 30 (29–48) | 9 (7–11) | 3 (2–3) | None: 3 (100) | None: 3 (100) | 2 (67) | Decline of KF: 3 (100) |
| IC-MPGN and C3G | 7 | 30 (14–55) | 1.3 (0.7–8) | 2 (2–4) | None: 2 (29) CS: 2 (29) CS+MMF: 1 (14) RTX: 1 (14) Aza: 1 (14) |
None: 6 (86) Infliximab: 1 (14) |
2 (29) | No remission: 4 (57) Partial remission: 3 (43) |
| AA amyloidosis | 4 | 29 (13–50) | 1.2 (0.9–4.4) | 3 (2–4) | None: 4 (100) | Budesonide: 1 (25) Adalimumab: 2 (50) Infliximab: 1 (25) |
1 (25) | No remission: 3 (75) Complete remission: 1 (25) |
| ANCA vasculitis | 2 | 27 | 0.7 | 2 | CS+CyC+Aza: 2 (100) | None: 2 (100) | 0 (0) | Complete remission: 2 (100) |
| MCD | 2 | 77 | 8 | 1 | CS+CNI: 2 (100) | None: 1 (50) Vedolizumab: 1 (50) |
0 (0) | Partial remission: 1 (50) Complete remission: 1 (50) |
| MN | 6 | 45 (30–84) | 6 (6–16) | 2 (1–4) | None: 1 (17) CS+CNI: 2 (33) RTX: 3 (50) |
None: 5 (6) | 3 (50) | No remission: 4 (67) Partial remission: 1 (17) Complete remission: 1 (17) |
| TMA | 1 | 14 | 3 | 3 | PEX: 1 (100) | None: 1 (100) | 0 (0) | Partial remission: 1 (100) |
| Fibrillary GN | 1 | 35 | 8 | 3 | None (100) | None: 1 (100) | 0 (0) | No remission: 1 (100) |
| Lupus nephritis | 1 | 107 | 5.3 | 1 | CS+MMF+CNI | None: 1 (100) | 0 (0) | Complete remission: 1 (100) |
| Thin basement membrane | 2 | 43 | 0.04 | 1 | None: 1 (100) | None: 2 (100) | 0 (0) | Improvement of KF: 2 (100) |
| LCPT | 1 | 81 | 5 | 1 | Clone-targeted therapy | None: 1 (100) | 0 (0) | Complete remission: 1 (100) |
AIN, acute interstitial nephritis; ANCA, antineutrophil cytoplasmic antibody; ATN, acute tubular necrosis; Aza, azathioprine; C3G, C3 glomerulopathy; CIN, chronic interstitial nephritis; CNI, calcineurin inhibitor; CS, corticosteroids; CyC, cyclophosphamide; eGFR, estimated glomerular filtration rate; GN, glomerulonephritis; IC-MPGN, immune complex-mediated membranoproliferative glomerulonephritis; IgAN, Immunoglobulin A nephropathy; IS, immunosuppressive; KF, kidney function; LCPT, light chain proximal tubulopathy; MCD, minimal change disease; MMF, mycophenolate mofetil; MN, membranous nephropathy; RTX, rituximab; TMA, thrombotic microangiopathy; UPCR, urinary protein-to-creatinine ratio.